Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 9202

Drug Profile

CV 9202

Alternative Names: BI 13618409; BI 1361849; CV-9202

Latest Information Update: 01 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim; Cancer Research Institute; CureVac; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 29 Oct 2021 Ludwig Institute for Cancer Research in collaboration with Boehringer Ingelheim and MedImmune completes the phase I/II trial in Non-small cell lung cancer in USA (NCT03164772)
  • 25 Sep 2020 CV 9202 is still in phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Intradermal) (NCT03164772)
  • 25 Sep 2020 CV 9202 is still in phase I/II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, In adults, In the elderly) in Spain (Intradermal) (EudraCT2015-001477-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top